EGFR and non-small cell lung carcinoma: In TKI-resistant EGFR-mutant metastatic non-squamous NSCLC, the most recent phase III data from the KEYNOTE-789 trial, evaluating the safety and effectiveness of combining pembrolizumab with chemotherapy, have demonstrated that pembrolizumab with chemotherapy did not significantly enhance PFS or OS over chemotherapy alone [94].